|
15 Companies |
|
22 Products |
|
22 Products |
|
12 Mechanisms of Action |
|
2 Trials |
|
254 News |
|
| «123456» |
- ||| Trial completion, Trial primary completion date: Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=250, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2015
- Trial completion, Trial primary completion date: ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=3, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Apr 2015
- Trial completion, Trial primary completion date, HEOR: FSHD1: Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=15, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Apr 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015
- Emflaza (deflazacort) / Marathon, PTC Therap
Trial primary completion date: A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Mar 11, 2015
P1, N=24, Recruiting, Sponsor: Marathon Pharmaceuticals, LLC
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Jan 2015 Trial primary completion date: Feb 2015 --> Jun 2015
- Trial primary completion date, Biopsy: Ultrasound in Muscle Biopsy (clinicaltrials.gov) - Mar 11, 2015
P=N/A, N=40, Enrolling by invitation, Sponsor: Duke University
Trial primary completion date: Feb 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- metformin / Generic mfg., L-citrulline / Generic mfg.
Trial primary completion date: L-citrulline and Metformin in Becker's Muscular Dystrophy (clinicaltrials.gov) - Mar 10, 2015
P2, N=20, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- ketamine / Generic mfg., dexmedetomidine / Generic mfg.
Biopsy: Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=53, Completed, Sponsor: Nationwide Children's Hospital
Trial primary completion date: Dec 2014 --> Dec 2015 N=19 --> 53
- prednisone / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy (clinicaltrials.gov) - Feb 19, 2015
P2, N=0, Withdrawn, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
N=19 --> 53 N=60 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Feb 2015
- || Trial primary completion date: Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=250, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
N=60 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Feb 2016 --> Feb 2015 Trial primary completion date: Jan 2015 --> Jan 2016
- Enrollment closed, Enrollment change, MRI: FSHD3: Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced. (clinicaltrials.gov) - Jan 29, 2015
P=N/A, N=15, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Trial primary completion date: Jan 2015 --> Jan 2016 Enrolling by invitation --> Active, not recruiting | N=30 --> 15
- Clinical: A Device for Rapid, Painless, Bedside Muscle Evaluation of Children (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=256, Recruiting, Sponsor: Skulpt, Inc.
- | BMN 044 / BioMarin
New P2 trial: Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Jan 2, 2015
P2, N=18, Enrolling by invitation, Sponsor: Prosensa Therapeutics
- Omigapil (SNT-317) / Santhera
New P1 trial: Congenital Muscular Dystrophy Study Analyzing Pharmacokinetics at Three Dose Levels in Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (clinicaltrials.gov) - Dec 30, 2014
P1, N=30, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
- Emflaza (deflazacort) / Marathon, PTC Therap
Enrollment open: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort (clinicaltrials.gov) - Dec 29, 2014
P1, N=24, Recruiting, Sponsor: Marathon Pharmaceuticals, LLC
Enrolling by invitation --> Active, not recruiting | N=30 --> 15 Not yet recruiting --> Recruiting
- Emflaza (deflazacort) / Marathon, PTC Therap
Enrollment open: A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Dec 29, 2014
P1, N=24, Recruiting, Sponsor: Marathon Pharmaceuticals, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- mexiletine / Generic mfg.
Trial primary completion date: Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 (clinicaltrials.gov) - Dec 7, 2014
P2, N=40, Recruiting, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2015 --> Dec 2015
- ||| Biomarker: MOS-DM1/POP: Multicenter Observational Study of Myotonic Dystrophy Type 1 (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=100, Recruiting, Sponsor: University of Rochester
- Emflaza (deflazacort) / Marathon, PTC Therap
New P1 trial: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort (clinicaltrials.gov) - Nov 20, 2014
P1, N=24, Not yet recruiting, Sponsor: Marathon Pharmaceuticals, LLC
- || Cabaletta (trehalose) / Seelos Therap
Trial primary completion date: HOPEMD: Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients (clinicaltrials.gov) - Nov 18, 2014
P2, N=60, Recruiting, Sponsor: Bioblast Pharma Ltd.
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Oct 2014 --> Jul 2015
- Trial primary completion date: The Effect of Aerobic Exercise, on Fitness and Functional Muscle Strength, in Patients With Muscular Dystrophy (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=8, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Oct 2014 --> Jul 2015 Trial primary completion date: Mar 2014 --> Dec 2014
- Trial completion, Enrollment change, Trial primary completion date: Duchenne Muscular Dystrophy Clinical Trial (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=6, Completed, Sponsor: Alan Neuromedical Technologies, LLC
Trial primary completion date: Mar 2014 --> Dec 2014 Recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Dec 2013 --> Sep 2014
- | lisinopril / Generic mfg.
Enrollment closed: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies (clinicaltrials.gov) - Oct 15, 2014
P2/3, N=120, Active, not recruiting, Sponsor: Cooperative International Neuromuscular Research Group
Recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Dec 2013 --> Sep 2014 Recruiting --> Active, not recruiting
- | Kyndrisa (drisapersen) / BioMarin
Trial termination, Trial primary completion date: Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Sep 29, 2014
P3, N=233, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Mar 2014; The study was formally terminated given that GSK is not submitting an application for regulatory approval for drisapersen in Duchenne Muscular Dystrophy.
- Emflaza (deflazacort) / Marathon, PTC Therap
New P1 trial: A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Sep 29, 2014
P1, N=24, Not yet recruiting, Sponsor: Marathon Pharmaceuticals, LLC
- Enrollment open: Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=24, Recruiting, Sponsor: University of Florida
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Mar 2014; The study was formally terminated given that GSK is not submitting an application for regulatory approval for drisapersen in Duchenne Muscular Dystrophy. Not yet recruiting --> Recruiting
- |||||| Kyndrisa (drisapersen) / BioMarin
Enrollment open, Enrollment change, Trial primary completion date: A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects (clinicaltrials.gov) - Sep 28, 2014
P3, N=67, Recruiting, Sponsor: Prosensa Therapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=23 --> 67 | Trial primary completion date: Mar 2015 --> Apr 2016
- New P1 trial: Cell Therapy in Limb Girdle Muscular Dystrophy (clinicaltrials.gov) - Sep 22, 2014
P1, N=200, Recruiting, Sponsor: Neurogen Brain and Spine Institute
- New P1 trial: Stem Cell Therapy in Duchenne Muscular Dystrophy (clinicaltrials.gov) - Sep 16, 2014
P1, N=500, Recruiting, Sponsor: Neurogen Brain and Spine Institute
- New P1 trial: Stem Cell Therapy in Muscular Dystrophy (clinicaltrials.gov) - Sep 16, 2014
P1, N=1000, Recruiting, Sponsor: Neurogen Brain and Spine Institute
- Enrollment closed, HEOR: A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: Cooperative International Neuromuscular Research Group
Active, not recruiting --> Recruiting | N=23 --> 67 | Trial primary completion date: Mar 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- | ezutromid (SMT C1100) / Sarepta Therap
Trial completion: A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - Aug 27, 2014
P1, N=12, Completed, Sponsor: Summit Corporation Plc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Cabaletta (trehalose) / Seelos Therap
Enrollment change: HOPEMD: Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients (clinicaltrials.gov) - Aug 4, 2014
P2, N=60, Recruiting, Sponsor: Bioblast Pharma Ltd.
Recruiting --> Completed N=28 --> 60
- tadalafil / Generic mfg.
New P4 trial: PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy (clinicaltrials.gov) - Aug 4, 2014
P4, N=12, Active, not recruiting, Sponsor: Cedars-Sinai Medical Center
- Trial primary completion date: Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy (clinicaltrials.gov) - Jul 27, 2014
P4, N=32, Recruiting, Sponsor: Centre d'Investigation Clinique et Technologique 805
N=28 --> 60 Trial primary completion date: Jun 2014 --> Apr 2015
- Trial primary completion date: Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients (clinicaltrials.gov) - Jul 23, 2014
P2, N=70, Enrolling by invitation, Sponsor: Coordinaci
Trial primary completion date: Jun 2014 --> Apr 2015 Trial primary completion date: Sep 2013 --> Sep 2014
- Clinical: Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy (clinicaltrials.gov) - Jul 18, 2014
P=N/A, N=250, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
- || Enrollment closed, HEOR: A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy. (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=250, Active, not recruiting, Sponsor: Prosensa Therapeutics
Trial primary completion date: Sep 2013 --> Sep 2014 Recruiting --> Active, not recruiting
- Biomarker: Variability of Molecular Biomarkers and Clinical Measures in People With Myotonic Dystrophy Type 1 (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=24, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
- prednisolone / Generic mfg.
New P2 trial: Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy (clinicaltrials.gov) - Jun 19, 2014
P2, N=24, Recruiting, Sponsor: Washington University School of Medicine
- Clinical: Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=50, Recruiting, Sponsor: Rigshospitalet, Denmark
- Enrollment open: HIT-FSHD: High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy (clinicaltrials.gov) - Jun 8, 2014
P=N/A, N=30, Recruiting, Sponsor: Grete Andersen, MD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Clinical: HIT-FSHD: High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=30, Recruiting, Sponsor: Grete Andersen, MD
- Trial completion: Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy (clinicaltrials.gov) - Jun 2, 2014
P1, N=16, Completed, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy (clinicaltrials.gov) - Jun 2, 2014
P1, N=20, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed N=36 --> 20
- ||| Catena (idebenone) / Santhera, Chiesi
Trial completion date: DELOS: Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - May 27, 2014
P3, N=65, Completed, Sponsor: Santhera Pharmaceuticals
N=36 --> 20 Trial completion date: Dec 2013 --> Apr 2014
- ||||| Catena (idebenone) / Santhera, Chiesi
Enrollment change: DELOS: Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - May 27, 2014
P3, N=65, Completed, Sponsor: Santhera Pharmaceuticals
Trial completion date: Dec 2013 --> Apr 2014 N=240 --> 65
- ||||||| Catena (idebenone) / Santhera, Chiesi
Trial completion: DELOS: Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD) (clinicaltrials.gov) - May 27, 2014
P3, N=65, Completed, Sponsor: Santhera Pharmaceuticals
N=240 --> 65 Active, not recruiting --> Completed
- Trial primary completion date: ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=3, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Aug 2014
- Trial completion date: ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=3, Recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: May 2014 --> Aug 2014 Trial completion date: May 2014 --> Nov 2014
- Enrollment change: FSHD2: Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With FSHD : Tolerance, Sustainability and Efficiency of Unsupervised Training Program. (clinicaltrials.gov) - May 4, 2014
P=N/A, N=15, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Trial completion date: May 2014 --> Nov 2014 N=30 --> 15